<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39380722</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2468-0427</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Infectious Disease Modelling</Title><ISOAbbreviation>Infect Dis Model</ISOAbbreviation></Journal><ArticleTitle>Impact of vaccination on Omicron's escape variants: Insights from fine-scale modelling of waning immunity in Hong Kong.</ArticleTitle><Pagination><StartPage>129</StartPage><EndPage>138</EndPage><MedlinePgn>129-138</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.idm.2024.09.006</ELocationID><Abstract><AbstractText>COVID-19 vaccine-induced protection declines over time. This waning of immunity has been described in modelling as a lower level of protection. This study incorporated fine-scale vaccine waning into modelling to predict the next surge of the Omicron variant of the SARS-CoV-2 virus. In Hong Kong, the Omicron subvariant BA.2 caused a significant epidemic wave between February and April 2022, which triggered high vaccination rates. About half a year later, a second outbreak, dominated by a combination of BA.2, BA.4 and BA.5 subvariants, began to spread. We developed mathematical equations to formulate continuous changes in vaccine boosting and waning based on empirical serological data. These equations were incorporated into a multi-strain discrete-time Susceptible-Exposed-Infectious-Removed model. The daily number of reported cases during the first Omicron outbreak, with daily vaccination rates, the population mobility index and daily average temperature, were used to train the model. The model successfully predicted the size and timing of the second surge and the variant replacement by BA.4/5. It estimated 655,893 cumulative reported cases from June 1, 2022 to 31 October 2022, which was only 2.69% fewer than the observed cumulative number of 674,008. The model projected that increased vaccine protection (by larger vaccine coverage or no vaccine waning) would reduce the size of the second surge of BA.2 infections substantially but would allow more subsequent BA.4/5 infections. Increased vaccine coverage or greater vaccine protection can reduce the infection rate during certain periods when the immune-escape variants co-circulate; however, new immune-escape variants spread more by out-competing the previous strain.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Yuling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Wing-Cheong</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Department of Mathematics, City University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ming</LastName><ForeName>Wai-Kit</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Public Health, City University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Hsiang-Yu</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Applied One Health Research and Policy Advice, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Infect Dis Model</MedlineTA><NlmUniqueID>101692406</NlmUniqueID><ISSNLinking>2468-0427</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Discrete-time simulation</Keyword><Keyword MajorTopicYN="N">Epidemic model</Keyword><Keyword MajorTopicYN="N">Immune-escape</Keyword><Keyword MajorTopicYN="N">Waning immunity</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>4</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39380722</ArticleId><ArticleId IdType="pmc">PMC11459622</ArticleId><ArticleId IdType="doi">10.1016/j.idm.2024.09.006</ArticleId><ArticleId IdType="pii">S2468-0427(24)00111-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bar-On Y.M., Goldberg Y., Mandel M., Bodenheimer O., Amir O., Freedman L., Alroy-Preis S., Ash N., Huppert A., Milo R. Protection by a fourth dose of BNT162b2 against Omicron in Israel. New England Journal of Medicine. 2022;386(18):1712–1720. doi: 10.1056/NEJMoa2201570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2201570</ArticleId><ArticleId IdType="pmc">PMC9006780</ArticleId><ArticleId IdType="pubmed">35381126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubar K.M., Reinholt K., Kissler S.M., Lipsitch M., Cobey S., Grad Y.H., Larremore D.B. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science (New York, N.Y.) 2021;371(6532):916–921. doi: 10.1126/science.abe6959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe6959</ArticleId><ArticleId IdType="pmc">PMC7963218</ArticleId><ArticleId IdType="pubmed">33479118</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Bai X., Chen X., Zheng N., Yang J., Zhang J., Yu H. Modeling the prediction on the efficacy of a homologous third dose of CoronaVac against SARS-CoV-2 Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 - China, 2020-2021. China CDC Weekly. 2023;5(5):103–107. doi: 10.46234/ccdcw2023.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2023.019</ArticleId><ArticleId IdType="pmc">PMC10061772</ArticleId><ArticleId IdType="pubmed">37006710</ArticleId></ArticleIdList></Reference><Reference><Citation>DATA.GOV.HK.  Daily count of vaccination by age groups. 2022. https://data.gov.hk/en-data/dataset/hk-hhb-hhbcovid19-vaccination-rates-over-time-by-age Available from:</Citation></Reference><Reference><Citation>Department of Health  The government of Hong Kong special administrative region. 2022. https://www.dh.gov.hk/english/index.html Available from:</Citation></Reference><Reference><Citation>Dick D.W., Childs L., Feng Z., Li J., Röst G., Buckeridge D.L., Ogden N.H., Heffernan J.M. COVID-19 seroprevalence in Canada modelling waning and boosting COVID-19 immunity in Canada a Canadian immunization Research network study. Vaccines. 2021;10(1):17. doi: 10.3390/vaccines10010017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10010017</ArticleId><ArticleId IdType="pmc">PMC8779812</ArticleId><ArticleId IdType="pubmed">35062678</ArticleId></ArticleIdList></Reference><Reference><Citation>Esterman, A. (2022). New Covid subvariants BA.4 and BA.5 are the most contagious yet – and driving Australia’s third Omicron wave. Available from: https://www.theguardian.com/world/2022/jul/05/new-covid-variants-ba4-ba5-most-contagious-australia-third-omicron-wave-coronavirus-subvariants-ba-4-5. (Accessed 5 July 2022).</Citation></Reference><Reference><Citation>Gazit S., Saciuk Y., Perez G., Peretz A., Pitzer V.E., Patalon T. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: Retrospective, test negative, case-control study. BMJ. 2022;377 doi: 10.1136/bmj-2022-071113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-071113</ArticleId><ArticleId IdType="pmc">PMC9127435</ArticleId><ArticleId IdType="pubmed">35609888</ArticleId></ArticleIdList></Reference><Reference><Citation>He S., Peng Y., Sun K. SEIR modeling of the COVID-19 and its dynamics. Nonlinear Dynamics. 2020;101(3):1667–1680. doi: 10.1007/s11071-020-05743-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11071-020-05743-y</ArticleId><ArticleId IdType="pmc">PMC7301771</ArticleId><ArticleId IdType="pubmed">32836803</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai N., Rawson T., Knock E.S., Sonabend R., Elmaci Y., Perez-Guzman P.N., Whittles L.K., Kanapram D.T., Gaythorpe K.A.M., Hinsley W., Djaafara B.A., Wang H., Fraser K., FitzJohn R.G., Hogan A.B., Doohan P., Ghani A.C., Ferguson N.M., Baguelin M., Cori A. Quantifying the effect of delaying the second COVID-19 vaccine dose in england: A mathematical modelling study. The Lancet Public Health. 2023;8(3):e174–e183. doi: 10.1016/S2468-2667(22)00337-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(22)00337-1</ArticleId><ArticleId IdType="pmc">PMC9910835</ArticleId><ArticleId IdType="pubmed">36774945</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D.S., Cromer D., Reynaldi A., Schlub T.E., Wheatley A.K., Juno J.A., Subbarao K., Kent S.J., Triccas J.A., Davenport M.P. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine. 2021;27(7):1205–1211. doi: 10.1038/s41591-021-01377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima N., Klausner J.D. Protective immunity after recovery from SARS-CoV-2 infection. The Lancet Infectious Diseases. 2022;22(1):12–14. doi: 10.1016/S1473-3099(21)00676-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00676-9</ArticleId><ArticleId IdType="pmc">PMC8575467</ArticleId><ArticleId IdType="pubmed">34762853</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok K.O., Li K.K., Tang A., Tsoi M.T.F., Chan E.Y.Y., Tang J.W.T., Wong A., Wei W.I., Wong S.Y.S. Psychobehavioral responses and likelihood of receiving COVID-19 vaccines during the pandemic, Hong Kong. Emerging Infectious Diseases. 2021;27(7):1802–1810. doi: 10.3201/eid2707.210054.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2707.210054</ArticleId><ArticleId IdType="pmc">PMC8237883</ArticleId><ArticleId IdType="pubmed">34152948</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau J.J., Cheng S.M.S., Leung K., Lee C.K., Hachim A., Tsang L.C.H., Yam K.W.H., Chaothai S., Kwan K.K.H., Chai Z.Y.H., Lo T.H.K., Mori M., Wu C., Valkenburg S.A., Amarasinghe G.K., Lau E.H.Y., Hui D.S.C., Leung G.M., Peiris M., Wu J.T. Author Correction: Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nature Medicine. 2024;30(1):305. doi: 10.1038/s41591-023-02648-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02648-2</ArticleId><ArticleId IdType="pmc">PMC10803247</ArticleId><ArticleId IdType="pubmed">37875568</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin E.G., Lustig Y., Cohen C., Fluss R., Indenbaum V., Amit S., Doolman R., Asraf K., Mendelson E., Ziv A., Rubin C., Freedman L., Kreiss Y., Regev-Yochay G. Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months. New England Journal of Medicine. 2021;385(24):e84. doi: 10.1056/NEJMoa2114583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114583</ArticleId><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang J.B., Yuan H.Y., Li K.K., Wei W.I., Wong S.Y.S., Tang A., Riley S., Kwok K.O. Path to normality: Assessing the level of social-distancing measures relaxation against antibody-resistant SARS-CoV-2 variants in a partially-vaccinated population. Computational and Structural Biotechnology Journal. 2022;20:4052–4059. doi: 10.1016/j.csbj.2022.07.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2022.07.048</ArticleId><ArticleId IdType="pmc">PMC9338450</ArticleId><ArticleId IdType="pubmed">35935805</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K., Lou Y. Optimizing COVID-19 vaccination programs during vaccine shortages. Infectious Disease Modelling. 2022;7(1):286–298. doi: 10.1016/j.idm.2022.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idm.2022.02.002</ArticleId><ArticleId IdType="pmc">PMC8872681</ArticleId><ArticleId IdType="pubmed">35233475</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Pearson C.A.B., Sandmann F.G., Barnard R.C., Kim J.H., Flasche S., Jit M., Abbas K., Cmmid Covid-19 Working Group Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis. The Lancet Regional Health. Europe. 2022;17 doi: 10.1016/j.lanepe.2022.100381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100381</ArticleId><ArticleId IdType="pmc">PMC8996067</ArticleId><ArticleId IdType="pubmed">35434685</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmud M.S., Kamrujjaman M., Adan M.M.Y., Hossain M.A., Rahman M.M., Islam M.S., Mohebujjaman M., Molla M.M. Vaccine efficacy and SARS-CoV-2 control in California and U.S. During the session 2020-2026: A modeling study. Infectious Disease Modelling. 2022;7(1):62–81. doi: 10.1016/j.idm.2021.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idm.2021.11.002</ArticleId><ArticleId IdType="pmc">PMC8627016</ArticleId><ArticleId IdType="pubmed">34869959</ArticleId></ArticleIdList></Reference><Reference><Citation>Menegale F., Manica M., Zardini A., Guzzetta G., Marziano V., d'Andrea V., Trentini F., Ajelli M., Poletti P., Merler S. Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: A systematic review and meta-analysis. JAMA Network Open. 2023;6(5) doi: 10.1001/jamanetworkopen.2023.10650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.10650</ArticleId><ArticleId IdType="pmc">PMC10157431</ArticleId><ArticleId IdType="pubmed">37133863</ArticleId></ArticleIdList></Reference><Reference><Citation>Najar F.Z., Linde E., Murphy C.L., Borin V.A., Wang H., Haider S., Agarwal P.K. Future COVID19 surges prediction based on SARS-CoV-2 mutations surveillance. Elife. 2023;12 doi: 10.7554/eLife.82980.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.82980</ArticleId><ArticleId IdType="pmc">PMC9894583</ArticleId><ArticleId IdType="pubmed">36655992</ArticleId></ArticleIdList></Reference><Reference><Citation>Our World in Data  How did the number of visitors change since the beginning of the pandemic? Hong Kong. 2022. https://ourworldindata.org/grapher/changes-visitors-covid?country=∼HKG Available from:</Citation></Reference><Reference><Citation>Peng Q., Zhou R., Wang Y., Zhao M., Liu N., Li S., Huang H., Yang D., Au K.K., Wang H., Man K., Yuen K.Y., Chen Z. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine. 2022;77 doi: 10.1016/j.ebiom.2022.103904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103904</ArticleId><ArticleId IdType="pmc">PMC8893246</ArticleId><ArticleId IdType="pubmed">35248996</ArticleId></ArticleIdList></Reference><Reference><Citation>Pérez-Then E., Lucas C., Monteiro V.S., Miric M., Brache V., Cochon L., Vogels C.B.F., Malik A.A., De la Cruz E., Jorge A., De Los Santos M., Leon P., Breban M.I., Billig K., Yildirim I., Pearson C., Downing R., Gagnon E., Muyombwe A., Razeq J.…Iwasaki A. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nature Medicine. 2022;28(3):481–485. doi: 10.1038/s41591-022-01705-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01705-6</ArticleId><ArticleId IdType="pmc">PMC8938264</ArticleId><ArticleId IdType="pubmed">35051990</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith T.P., Flaxman S., Gallinat A.S., Kinosian S.P., Stemkovski M., Unwin H.J.T., Watson O.J., Whittaker C., Cattarino L., Dorigatti I., Tristem M., Pearse W.D. Temperature and population density influence SARS-CoV-2 transmission in the absence of nonpharmaceutical interventions. Proceedings of the National Academy of Sciences of the United States of America. 2021;118(25) doi: 10.1073/pnas.2019284118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2019284118</ArticleId><ArticleId IdType="pmc">PMC8237566</ArticleId><ArticleId IdType="pubmed">34103391</ArticleId></ArticleIdList></Reference><Reference><Citation>The Government of Hong Kong Special Administrative Region  CHP investigates locally acquired SARS-CoV-2 virus cases with 1 052 cases tested positive by nucleic acid tests and 2 929 cases by RATs as well as 437 imported cases. 2022. https://www.info.gov.hk/gia/general/202211/01/P2022110100517.htm Available from:</Citation></Reference><Reference><Citation>The Government of Hong Kong Special Administrative Region  COVID-19 thematic website - together, we fight the virus. 2022. https://www.coronavirus.gov.hk/eng/index.html Available from:</Citation></Reference><Reference><Citation>The Government of Hong Kong Special Administrative Region  Vaccine pass. 2022. https://www.coronavirus.gov.hk/eng/vaccine-pass.html Available from:</Citation></Reference><Reference><Citation>The Government of Hong Kong Special Administrative Region  Announcement of appointment arrangements for shortened intervals between COVID-19 vaccine doses. 2022. https://www.info.gov.hk/gia/general/202203/04/P2022030400691.htm Available from:</Citation></Reference><Reference><Citation>Thompson M.G., Burgess J.L., Naleway A.L., Tyner H.L., Yoon S.K., Meece J., Olsho L.E.W., Caban-Martinez A.J., Fowlkes A., Lutrick K., Kuntz J.L., Dunnigan K., Odean M.J., Hegmann K.T., Stefanski E., Edwards L.J., Schaefer-Solle N., Grant L., Ellingson K., Groom H.C.…Gaglani M. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - eight U.S. Locations, December 2020-March 2021. Morbidity &amp; Mortality Weekly Report. 2021;70(13):495–500. doi: 10.15585/mmwr.mm7013e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7013e3</ArticleId><ArticleId IdType="pmc">PMC8022879</ArticleId><ArticleId IdType="pubmed">33793460</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. 2023. https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic Available from:</Citation></Reference><Reference><Citation>Yuan H.Y., Liang J., Hossain M.P. Impacts of social distancing, rapid antigen test and vaccination on the Omicron outbreak during large temperature variations in Hong Kong: A modelling study. Journal of Infection and Public Health. 2022;15(12):1427–1435. doi: 10.1016/j.jiph.2022.10.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2022.10.026</ArticleId><ArticleId IdType="pmc">PMC9633629</ArticleId><ArticleId IdType="pubmed">36395667</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Kong Observatory  Highlight of Hong Kong climate. 2022. https://www.hko.gov.hk/en/cis/climat.htm Available from:</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>